about
A common haplotype in the G-protein-coupled receptor gene GPR74 is associated with leanness and increased lipolysisPhysical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activityThe roles of nerve growth factor and cholecystokinin in the enhancement of morphine analgesia in a rodent model of central nervous system inflammationHeterologous regulation of Mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells.Metabolism of cryptic peptides derived from neuropeptide FF precursors: the involvement of insulin-degrading enzyme.Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptorsIdentification and functional characterization of the phosphorylation sites of the neuropeptide FF2 receptor.Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potentialBiomarkers in chronic adult hydrocephalus.Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats.Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice.Lipid-Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer.Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in miceOpioid system and Alzheimer's disease.Biological properties and perspective applications of "Bio-neuter" chemicals?The prolactin-releasing peptide antagonizes the opioid system through its receptor GPR10.NPYFa, A Chimeric Peptide of Met-Enkephalin, and NPFF Induces Tolerance-Free Analgesia.Pain regulation of endokinin A/B or endokinin C/D on chimeric peptide MCRT in mice.Understanding the Agent, Part I: Opioid Biology and Basic Pharmacology
P2860
Q24669981-22AC2D6F-6E15-41E0-84D6-1CE8C74A2647Q28283440-E710AD19-BBB4-4D98-B3E2-8EEE9403C1A9Q28579164-58B25F02-6C61-4CCA-8446-17AD1A257606Q34317508-47CC46E6-4C1F-4A55-BC58-1AB13BD52D3EQ34358968-C6E63EDE-7B26-4D23-AA9E-B7D86273FD13Q34525251-F0EFD558-CA0A-448F-A56A-7EA38ED03102Q34634103-63979585-989C-48F5-A4D1-70964F459B9CQ34712671-63F328CB-C176-4183-B25C-A77D6E0F6114Q35101048-C2750816-CBDE-4093-8CC5-54787C1929D1Q35127461-1A39940E-0B8B-4CDB-8F9B-2822596E826EQ35218957-6DFA208D-CEF3-47B5-8DA3-680F0D24D433Q35563739-F12421EB-9049-42C2-9BA5-86E1540A532EQ35708164-C0CD738E-BED0-4938-AE07-A4D8748CC857Q35921655-3947FC7B-F502-4692-A073-D6EEBC4114C2Q36903414-B7393D8E-7904-403F-A4BC-81EF3C613723Q38004941-0A73D637-9342-4848-B4B9-55EFD3FA351FQ41905629-F0BC0011-F93A-4F2C-9459-EFA1C9F7DDCCQ44351059-0FF51CF0-55E7-4FA8-AD36-E51A57AA65E8Q48255291-32A17252-8321-458A-AA75-97784DB7039CQ50629865-A19E2505-9494-464A-8F2E-DD307BDEAE07Q57462903-C9598BF2-861D-44D0-B696-F82C2C3319C6
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Opioid-modulating peptides: mechanisms of action.
@ast
Opioid-modulating peptides: mechanisms of action.
@en
type
label
Opioid-modulating peptides: mechanisms of action.
@ast
Opioid-modulating peptides: mechanisms of action.
@en
prefLabel
Opioid-modulating peptides: mechanisms of action.
@ast
Opioid-modulating peptides: mechanisms of action.
@en
P356
P1476
Opioid-modulating peptides: mechanisms of action.
@en
P2093
Jean-Marie Zajac
Michel Roumy
P304
P356
10.2174/1568026053544515
P50
P577
2005-01-01T00:00:00Z